IFN Signaling and ICB Resistance: Time is on Tumor's Side.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Trends in Cancer

• Publication date

  2017-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.trecan.2017.01.004PMID 28718428
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.

  2016cited by this paper
• Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

  2016cited by this paper
• Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

  2016cited by this paper
• Acquired resistance to immunotherapy and future challenges

  2016cited by this paper
• Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

  2016cited by this paper
• Immune checkpoint blockade and interferon-α in melanoma.

  2015cited by this paper
• Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression

  2015cited by this paper
• Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

  2014cited by this paper
• Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

  2012cited by this paper
• Impaired interferon signaling is a common immune defect in human cancer

  2009cited by this paper

• Fasting-mimicking diet induces IFNβ secretion in tumor-associated macrophages via NRF1-mediated ubiquitin-dependent proteolysis of Trex1.

  2026cites this paper
• Therapeutic Options Targeting the Ataxia-Telangiectasia Mutated (ATM)-mediated DNA Damage Response, Macropinocytosis, and Adaptive Immunity in Ovarian Cancer

  2024cites this paper
• Multi-omics analysis reveals cuproptosis and mitochondria-based signature for assessing prognosis and immune landscape in osteosarcoma

  2024cites this paper
• Modern cancer therapy: cryoablation meets immune checkpoint blockade

  2024cites this paper
• Integration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer

  2024cites this paper
• POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1

  2024cites this paper
• Hyper-Interferon Sensitive Influenza Induces Adaptive Immune Responses and Overcomes Resistance to Anti–PD-1 in Murine Non–Small Cell Lung Cancer

  2024cites this paper
• Tumor cells inhibit the activation of ILC2s through up-regulating PD-1 expression

  2024cites this paper
• Fullerene‐Based Immunoregulatory Nanomaterials for Immunotherapy of Tumor and Immune‐Related Inflammatory Diseases

  2024cites this paper
• Harnessing innate immune pathways for therapeutic advancement in cancer

  2024cites this paper
• Inhibiting interferon-γ induced cancer intrinsic TNFRSF14 elevation restrains the malignant progression of glioblastoma

  2024cites this paper
• Identification of prognostic genes for breast cancer related to systemic lupus erythematosus by integrated analysis and machine learning.

  2023cites this paper
• Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma.

  2023cites this paper
• Macrophages facilitate tumor cell PD‐L1 expression via an IL‐1β‐centered loop to attenuate immune checkpoint blockade

  2023cites this paper
• Harnessing type I interferon-mediated immunity to target malignant brain tumors

  2023cites this paper
• Guanylate‐binding proteins signature predicts favorable prognosis, immune‐hot microenvironment, and immunotherapy response in hepatocellular carcinoma

  2023cites this paper
• FAM120A couples SREBP-dependent transcription and splicing of lipogenesis enzymes downstream of mTORC1.

  2023cites this paper
• 131I-αPD-L1 immobilized by bacterial cellulose for enhanced radio-immunotherapy of cancer.

  2022cites this paper
• Fibroblast Activation Protein-Alpha is a Prognostic Biomarker Associated With Ferroptosis in Stomach Adenocarcinoma

  2022cites this paper
• ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas

  2021cites this paper
• Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression

  2021cites this paper
• Implantable and Injectable Biomaterial Scaffolds for Cancer Immunotherapy

  2020cites this paper
• Trial watch: Immune checkpoint blockers for cancer therapy

  2017influential citation